The Adoptive Cell Therapy (ACT) market was impacted by data presented during the American Society of Hematology (ASH) meeting in Orlando, FL.

Breaking Data will worked with 30 oncologists during the meeting to better understand the commercial implications of data presented for: CC-93269 (anti-BCMA), JNJ-4528/LCAR-B38M (anti-BCMA), bb21217 (anti-BCMA), CT103A (anti-BCMA), lisocabtagene maraleucel (liso-cel), PBCAR0191 (allogenic CAR-T).

Companies presenting data include: Celgene/BMS, Janssen, bluebird bio, IASO BIO, Precision BioSciences.

Get immediate access to this 60-slide report so you can make better decisions today and prepare for tomorrow.

ADOPTIVE CELL THERAPY REPORT ASH 2019

Orlando, FL
Dec 7 to Dec 11

Share: